Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...

Obesity influences the thresholds, but even in nonobese patients with dyspnea, optimal cutoffs may be lower than recommended.

Middle aged and older adults who are hospitalized for severe infections were more than twice as likely to develop heart failure in the future, a new study shows. Authors say that’s why it’s so ...

Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Patients with rheumatoid arthritis are associated with an increased risk for heart failure, particularly heart failure with preserved ejection fraction.

Researchers from the Nagoya University Graduate School of Medicine identified an enzyme, alpha-kinase 2 (ALPK2) that is ...

What is ALPK2, and how can it help treat heart failure? Researchers have found that this heart-specific enzyme may prevent ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.